(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 May 2019 (31.05.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/104092 A1

(51) International Patent Classification:
A61K 38/20 (2006.01) *C12N 15/09* (2006.01)
C07K 14/54 (2006.01) *C12N 15/11* (2006.01)
C07K 14/55 (2006.01)

(21) International Application Number:
PCT/US2018/062122

(22) International Filing Date:
20 November 2018 (20.11.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/589,497 21 November 2017 (21.11.2017) US

(71) Applicant: **THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY** [US/US]; 3000 El Camino Real, Building 5, Suite 300, Palo Alto, California 94306 (US).

(72) Inventors: **GARCIA, Christopher K.**; 3000 El Camino Real, Building 5, Suite 300, Palo Alto, California 94306 (US). **MAJRI, Sonia S.**; 3000 El Camino Real, Building 5, Suite 300, Palo Alto, California 94306 (US). **GLASSMAN, Caleb R.**; General Counsel, Building 170, 3rd Floor, Main Quad, P.O. Box 20386, Stanford, California 94305-2038 (US). **SU, Leon Lih-Ren**; General Counsel, Building 170, 3rd Floor, Main Quad, P.O. Box 20386, Stanford, California 94305-2038 (US).

(74) Agent: **DANG, David V.** et al.; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, Massachusetts 02111 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

(54) Title: PARTIAL AGONISTS OF INTERLEUKIN-2



FIG. 1

(57) **Abstract:** Provided herein, inter alia, are human interleukin-2 (IL-2) muteins or variants thereof. In particular, provided herein are IL-2 muteins that have a decreased binding capacity for IL-2R$_\gamma$. Such IL-2 muteins are useful, for example, as IL-2 partial agonist in applications where reduction or inhibition of one or more IL-2 and/or IL- 15 functions is useful (*e.g.*, in the treatment of autoimmune diseases or conditions). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.

[Continued on next page]

WO 2019/104092 A1

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*